FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease
- 18 October 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (47) , 4789-4790
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 DiabetesNew England Journal of Medicine, 2021
- Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology CommunityCirculation, 2021
- Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 DiabetesCirculation, 2021
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2020
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet Diabetes & Endocrinology, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019